Featured Research

from universities, journals, and other organizations

Interleukin-10 may be prognostic factor in treatment with autologous melanoma vaccine

Date:
June 7, 2010
Source:
Thomas Jefferson University
Summary:
Scientists from the Kimmel Cancer Center at Jefferson have found that interleukin-10 production in tumor cells is a possible prognostic factor in patients with advanced melanoma who are treated with autologous melanoma cell vaccine.

Scientists from the Kimmel Cancer Center at Jefferson have found that interleukin-10 production in tumor cells is a possible prognostic factor in patients with advanced melanoma who are treated with autologous melanoma cell vaccine.

Related Articles


They are presenting their data at the 2010 ASCO Annual Meeting in Chicago (Abstract #8588).

"High production of interleukin-10 (IL-10) in the tumor cells was associated with worse prognosis after patients receive the vaccine," said Amit Mahipal, M.D., a fellow in Hematology/Oncology at Jefferson Medical College of Thomas Jefferson University, and lead author of the study. "Because it downregulates the T cell-mediated immune response, high IL-10 levels in the tumor microenvironment may decrease the effectiveness of the vaccine."

An autologous cancer vaccine is a treatment created from a patient's own tumor cells. When the vaccine is administered to the patient, it may elicit an immune response and kill the tumor cells. IL-10 is a cytokine that plays a major role in adjusting the degree of immune response. It has previously been shown that high IL-10 levels in the blood indicate progression of metastatic melanoma.

In the study, led by Takami Sato, M.D., professor of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, the researchers evaluated 44 patients with stage III and stage IV melanoma. Tumor cells were extracted from melanoma tissues and preserved for vaccine production. Prior to vaccine production, the researchers separated a small portion of melanoma cells from the tissues. These small portions were then cultured for the production of IL-10. The tumor specimens were used for autologous cancer cell vaccine after modification with a chemical called dinitrophenyl (DNP), which makes tumor cells more foreign to the host immune system.

Overall, the median overall survival for high IL-10 producers was 10.5 months vs. 42 months for low IL-10 producers. The difference in median overall survival was more striking in patients with stage III disease: 9.7 months for high IL-10 producers vs. 84 months for low producers. For stage IV disease, the overall survival for high IL-10 producers was 10.5 months vs. 13.7 months for low producers.

"We think that the vaccine treatment may be more effective if you combine the cancer vaccine with a blockade of IL-10," Dr. Mahipal said.

A specific blockade for IL-10 was already developed and is under investigation by Dr. Sato's group at Thomas Jefferson University.


Story Source:

The above story is based on materials provided by Thomas Jefferson University. Note: Materials may be edited for content and length.


Cite This Page:

Thomas Jefferson University. "Interleukin-10 may be prognostic factor in treatment with autologous melanoma vaccine." ScienceDaily. ScienceDaily, 7 June 2010. <www.sciencedaily.com/releases/2010/06/100607101804.htm>.
Thomas Jefferson University. (2010, June 7). Interleukin-10 may be prognostic factor in treatment with autologous melanoma vaccine. ScienceDaily. Retrieved March 30, 2015 from www.sciencedaily.com/releases/2010/06/100607101804.htm
Thomas Jefferson University. "Interleukin-10 may be prognostic factor in treatment with autologous melanoma vaccine." ScienceDaily. www.sciencedaily.com/releases/2010/06/100607101804.htm (accessed March 30, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, March 30, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins